Evidence map›Paper›PMID 37558318›Full record

ArticleChest2023

Does Vancomycin-Piperacillin-Tazobactam Cause Pseudo-AKI, True Nephrotoxicity, or Both?

Jean-Maxime Côté, Michaël Desjardins, Patrick T Murray

Registry-linked trialAbstract readEditorialComment
PubMed Publisher
In one paragraph

Article in Chest, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07556107 (A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07556107 phase4recruitingnot on this mapstarted 2026, after this paper: background citation

A Randomized Controlled Trial Comparing Renal Effects of Vancomycin Combined With Either Piperacillin/Tazobactam or Meropenem: VPT Patient Safety (VPS) Study

TypeinterventionalSponsorBassett HealthcareRan2026 to 2028Enrolled852ConditionsInfection, Acute Kidney Injury, SepsisArmsPiperacillin + Tazobactam, meropenem
3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Observational
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jean-Maxime CôtéFaculty of Medicine, University of Montreal, Montreal, QC, Canada; CHUM Research Center (CRCHUM), Montreal, QC, Canada; Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada. Electronic address: jean-maxime.cote@umontreal.ca.
Michaël DesjardinsFaculty of Medicine, University of Montreal, Montreal, QC, Canada; CHUM Research Center (CRCHUM), Montreal, QC, Canada; Centre hospitalier de l'Université de Montréal, Montreal, QC, Canada.
Patrick T MurrayFaculty of Medicine, University College Dublin, Dublin, Ireland; Mater Misericordiae University Hospital, Dublin, Ireland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acute Kidney InjuryVancomycinAnti-Bacterial AgentsDrug Therapy, CombinationHumansPiperacillin, Tazobactam Drug CombinationRetrospective StudiesAnti-Bacterial AgentsPiperacillin, Tazobactam Drug CombinationVancomycin

Identifiers

PMID37558318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.